Tag Archive for: Infectious Diseases

Biocomposites invests in InfectoTest GmbH – developers of a bacterial-specific point-of-care test for periprosthetic joint infection (PJI)

/in

InfectoSynovia is being developed to provide a high-accuracy bedside test that can diagnose PJI in less than five minutes It is based on InfectoTest’s ability to detect the infection in tiny quantities of synovial fluid using a unique method of electrochemical analysis The investment signifies Biocomposites’ ongoing commitment to providing products for the management of […]

Read more

Biocomposites acquires remaining shares in manufacturers of SYNICEM™ and Subiton products

/in

SYNICEM™ and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers support surgeons’ infection treatment strategiesLaboratorios SL S.A. and Synergie Ingénierie Médicale S.A.R.L. are the manufacturers of SYNICEM™ and Subiton products Keele, UK, 18 September 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone […]

Read more

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer

/in

Experienced, innovative biotech and pharma leader with demonstrated success in discovery and development of new therapeutic technologies  Amsterdam, NLD – 5 December 2023 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as […]

Read more

Poolbeg Pharma plc – Positive Conclusion Reached in Immunomodulator I Patent Opposition

/in

29 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge to the Company’s European patent (Immunomodulator I), has been cancelled. This favourably […]

Read more

Poolbeg Pharma plc – Immunomodulator I Patent Portfolio Strengthened

/in

20 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application. Read more…

Read more